ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
2026 ARDC Annual Survey is now open!

The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your interaction with the ARDC and use of our national research infrastructure and services. The survey will take approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure services including Reasearch Link Australia.

We will use the information you provide to improve the national research infrastructure and services we deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research Infrastructure Strategy (NCRIS) program.

Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.

Complete the 5 min survey now by clicking on the link below.

Take Survey Now

Thank you.

  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Scheme : NHMRC Strategic Awards
Research Topic : Drug mechanism of action
Clear All
Filter by Field of Research
Ophthalmology and optometry not elsewhere classified (6)
Medical and Health Sciences (4)
Medical and Health Sciences not elsewhere classified (4)
Geriatrics And Gerontology (3)
Optical technology (3)
Public Health and Health Services (3)
Clinical Sciences not elsewhere classified (2)
Infectious Diseases (2)
Oncology And Carcinogenesis (2)
Applied immunology (incl. antibody engineering xenotransplantation and t-cell therapies) (1)
Behavioural economics (1)
Epidemiology (1)
Genome Structure and Regulation (1)
Haematological tumours (1)
Health and Community Services (1)
Humoural immunology and immunochemistry (1)
Immunology not elsewhere classified (1)
Inorganic green chemistry (1)
Medical biochemistry - amino acids and metabolites (1)
Nutrigenomics and personalised nutrition (1)
Preventive Medicine (1)
Psychiatry (incl. Psychotherapy) (1)
Respiratory Diseases (1)
Social and Community Psychology (1)
Vision science (1)
Filter by Socio-Economic Objective
Search did not return any results.
Filter by Funding Provider
National Health and Medical Research Council (45)
Filter by Status
Closed (45)
Filter by Scheme
NHMRC Strategic Awards (45)
Filter by Country
Australia (2)
Filter by Australian State/Territory
VIC (2)
  • Researchers (0)
  • Funded Activities (45)
  • Organisations (30)
  • Funded Activity

    Injecting Drug Users: Social Networks And Molecular Epidemiology Of The Hepatitis C Virus

    Funder
    National Health and Medical Research Council
    Funding Amount
    $543,868.00
    Summary
    The hepatitis C virus (HCV) continues to spread among injecting drug users (IDUs) in Australia at a very high rate, despite success in preventing the spread of HIV in the same groups; the complete reasons for this remain unclear. There is an urgent need for the HCV epidemic among IDUs to be contained. To do so, we must better understand the ways in which it is spreading among IDUs. Much is known about risk behaviours of individual IDUs and how they contribute to HCV transmission; much less is kn .... The hepatitis C virus (HCV) continues to spread among injecting drug users (IDUs) in Australia at a very high rate, despite success in preventing the spread of HIV in the same groups; the complete reasons for this remain unclear. There is an urgent need for the HCV epidemic among IDUs to be contained. To do so, we must better understand the ways in which it is spreading among IDUs. Much is known about risk behaviours of individual IDUs and how they contribute to HCV transmission; much less is known about how these behaviours are modified by the influence of the IDUs peer group, especially their immediate and intimate social networks. Despite its importance in influencing attitudes and behaviours, and therefore HCV transmission, this has never been studied in Australia, nor, in relation to HCV, in the world. We hope that by studying social and risk networks of IDUs we shall discover new ways in which control of the HCV epidemic can be achieved in Australia. We intend to do this among two groups of young IDUs, one of Vietnamese ethnicity, located in the one suburb of Melbourne. By using field techniques for gathering information (ethnography), and sophisticated analytic techniques to understand how these networks are formed and influence behaviours, we hope to be able to identify interventions which work at the level of the social group rather than the individual in bringing about the behaviour change necessary to prevent HCV transmission. To ensure that the risk networks we describe are as influential as they appear, and to discover more about the variability of HCV, we will also be investigating the relationship between the various strains of HCV in members of the IDU networks, particularly as another measure of the connectedness of networks and network members. This will be done using sophisticated genetic analysis of the HCV obtained from network members by blood test.
    Read more Read less
    More information
    Funded Activity

    Barriers To Accessing Mainstream Drug And Alcohol Services By Kooris Who Use Injecting Drugs

    Funder
    National Health and Medical Research Council
    Funding Amount
    $126,456.00
    More information
    Funded Activity

    Sensitive, Rapid And Accurate Detection Of The Emergence Of Neuraminidase Inhibitor Resistance By Real-time PCR, LCR And

    Funder
    National Health and Medical Research Council
    Funding Amount
    $118,875.00
    Summary
    An influenza pandemic causing by highly pathogenic H5N1 virus may occur in the near future. As a vaccine for H5N1 will not be available in the foreseeable months, antiviral drugs are the only possible choice for prophylaxis and treatment. Currently only two drugs have been clinically proven to be effective against H5N1 strain and the emergence of drug resistant in H5N1 influenza virus has been reported which may significantly hamper the treatment. Understanding and monitoring the emergence of th .... An influenza pandemic causing by highly pathogenic H5N1 virus may occur in the near future. As a vaccine for H5N1 will not be available in the foreseeable months, antiviral drugs are the only possible choice for prophylaxis and treatment. Currently only two drugs have been clinically proven to be effective against H5N1 strain and the emergence of drug resistant in H5N1 influenza virus has been reported which may significantly hamper the treatment. Understanding and monitoring the emergence of these drug resistant strains during local spreading will be critical in managing an H5N1 influenza pandemic in Australia. In the proposed project, we will develop important diagnostic tools using our world leading Rolling Circle Amplification (RCA) technology for the monitoring of the development and possible transmission of drug resistant influenza strains. Upon finishing the project, at lease three sensitive diagnostic methods will be developed for the detection of the emergence of drug resistance at the very early stage.
    Read more Read less
    More information
    Funded Activity

    Australian Ageing Alliance: Geriatric Pharmacology

    Funder
    National Health and Medical Research Council
    Funding Amount
    $162,750.00
    More information
    Funded Activity

    Assessment Of Development Of Resistance To Neuraminidase Inhibitors In A (H5N1) Influenza Viruses Using A Ferret Model

    Funder
    National Health and Medical Research Council
    Funding Amount
    $165,546.00
    Summary
    The neuraminidase (NA) inhibitors are considered the most effective anti-influenza drugs available for both prevention and treatment of influenza virus infection including A(H5N1) viruses. The drugs are effective against all subtypes of influenza A, making them ideal for use in the early months of a pandemic prior to an appropriate vaccine being produced. As a result many countries around the world, including Australia, have stockpiled these drugs (mainly Tamiflu) as part of their pandemic prepa .... The neuraminidase (NA) inhibitors are considered the most effective anti-influenza drugs available for both prevention and treatment of influenza virus infection including A(H5N1) viruses. The drugs are effective against all subtypes of influenza A, making them ideal for use in the early months of a pandemic prior to an appropriate vaccine being produced. As a result many countries around the world, including Australia, have stockpiled these drugs (mainly Tamiflu) as part of their pandemic preparedness plans. However, of concern is the increasing number of recent reports of a higher than expected level of resistance in epidemic influenza being generated against these drugs. A recent isolation of an H5N1 virus from a Vietnamese girl highlights that these viruses can also be resistant to Tamiflu. Within Australia, Tamiflu will be a critical weapon against the initial wave of an influenza pandemic, therefore it is vital that more is known about the propensity of the H5N1 virus to generate resistance, and possibly make these drugs clinically less effective. The aim of the project is to determine the levels, mode and type of resistance that may occur when ferrets are experimentally infected with HP A(H5N1) virus and then treated with NA inhibitors drugs such as Tamiflu. In the event of resistant viruses being isolated following drug pressure from Tamiflu, the strains will then be tested for their sensitivity to the other NA inhibitor drugs Relenza (zanamivir) or the peramivir (a third currently unlicensed NA inhibitor). The results from this cross resistance work will allow strategies to be put into place regarding the administration of an alternative NA inhibitor in the event of a pandemic virus acquiring particular NA mutations which may for example result in Tamiflu resistance. To determine the relative human risk of a NA inhibitor resistant A(H5N1) virus, studies to determine how infectious or transmissible the viruses are would be performed on all resistant strains isolated. NA inhibitor resistant strains demonstrate varying degrees of transmissibility and fitness, therefore it would be beneficial to classify this for any strains generated from this study so as to be in a better position to understand the public health implications if a particular resistant strain was to arise.
    Read more Read less
    More information
    Funded Activity

    Screening Agents Active Against The Late-stage Inflammatory Cytokines For Activity Against Influenza Disease

    Funder
    National Health and Medical Research Council
    Funding Amount
    $241,409.00
    Summary
    Infection with a virulent influenza virus that the body has never encountered before, particularly H5N1, sends the immune system into overdrive, and causes a massive release of proteins (inflammatory cytokines), known as a cytokine storm, that in and of itself leads to death. The object of this research is to screen, in a mouse influenza model, agents known to prevent this occurring and antagonise it once it has occurred. This will be done with and without Tamiflu, a standard anti-influenza drug .... Infection with a virulent influenza virus that the body has never encountered before, particularly H5N1, sends the immune system into overdrive, and causes a massive release of proteins (inflammatory cytokines), known as a cytokine storm, that in and of itself leads to death. The object of this research is to screen, in a mouse influenza model, agents known to prevent this occurring and antagonise it once it has occurred. This will be done with and without Tamiflu, a standard anti-influenza drug.
    Read more Read less
    More information
    Funded Activity

    Optimising Current Therapeutic Approaches To Schizophrenia: The OPTiMiSE Consortium

    Funder
    National Health and Medical Research Council
    Funding Amount
    $1,016,659.00
    Summary
    Despite modern treatments advances (medications and psychological treatments), the prognosis of schizophrenia has only improved marginally and is individually variable. The OPTiMiSE Consortium, consisting of leading experts in schizophrenia research across Europe and a group in Australia, will commence a 5-year research program world-first in scale and scope. We will investigate the biological markers related to treatment response in over 1000 individuals with recent-onset schizophrenia. Schizop .... Despite modern treatments advances (medications and psychological treatments), the prognosis of schizophrenia has only improved marginally and is individually variable. The OPTiMiSE Consortium, consisting of leading experts in schizophrenia research across Europe and a group in Australia, will commence a 5-year research program world-first in scale and scope. We will investigate the biological markers related to treatment response in over 1000 individuals with recent-onset schizophrenia. Schizophrenia is a chronic disease and despite modern medication and psychological treatments the outcome is highly variable and often poor. The Melbourne Neuropsychiatry Centre is part of the European based OPTiMiSE Consortium, the largest ever research program evaluating why individuals with schizophrenia vary in response to different medications. We will examine what characteristics predict which drugs are most helpful to 120 individuals with first episode schizophrenia
    Read more Read less
    More information
    Funded Activity

    Sustainability Of Evidence Based Behavioural Change Intervention: Converting Evidence Into Practice Airway Disease DEPAD

    Funder
    National Health and Medical Research Council
    Funding Amount
    $10,024.00
    More information
    Funded Activity

    Research & Training To Reduce Morbidity & Mortality From Malaria In Papua ( Indonesia)& Papua New Guinea

    Funder
    National Health and Medical Research Council
    Funding Amount
    $1,649,828.00
    Summary
    Malaria kills many thousands of people each year in Indonesia and PNG. This project will look at better ways to treat and prevent malaria. The team will examine whether using new combinations of drugs in clinics can reduce the amount of severe malaria seen in Papua. The team will examine whether giving people with severe malaria arginine, a naturally occurring amino acid, can increase molecules that may protect against severe malaria. Finally it will examine how lung damage occurs in people with .... Malaria kills many thousands of people each year in Indonesia and PNG. This project will look at better ways to treat and prevent malaria. The team will examine whether using new combinations of drugs in clinics can reduce the amount of severe malaria seen in Papua. The team will examine whether giving people with severe malaria arginine, a naturally occurring amino acid, can increase molecules that may protect against severe malaria. Finally it will examine how lung damage occurs in people with severe malaria and whether this can be predicted.
    Read more Read less
    More information
    Funded Activity

    PASSPORTS TO ADVANTAGE: Health And Capacity Building As A Basis For Social Integration

    Funder
    National Health and Medical Research Council
    Funding Amount
    $1,894,012.00
    Summary
    This project will conduct a randomised controlled trial of a post-release intervention for adult prisoners in Queensland. The findings of the study will inform the development of an evidence-based post-release intervention for prisoners in Australia and elsewhere, as well as providing an unprecedented insight into the post-release experiences of prisoners in Queensland.
    More information

    Showing 1-10 of 45 Funded Activites

    • 1
    • 2
    • 3
    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback